Michelle Fernandez
Nurse Practitioner · Las Vegas, NVNPI 1730833799
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,717 of the $8,650 with a category attached, or 89.2%. 38 manufacturers reported payments, led by Abbott at 26.2% of the total. Among nurse practitioner clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 394 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- AbbVie$2K
- Novartis$656
- Pfizer$569
- Argenx US, Inc.$429
- Lundbeck LLC$424
- plus $3K from 32 others
What the payments were for
- Travel & lodging$93211%
- Food & beverage$7,71789%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$1,764
How this compares
$8,650 in reported general payments places this provider in the 95th percentile of 933 nurse practitioner providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 11 | $64,152 |
| QuliptaAtogepant | 29 | $34,378 |
| Emgality PenGalcanezumab-Gnlm | 21 | $14,699 |
| Memantine Hcl | 304 | $4,339 |
| Donepezil Hcl | 468 | $2,591 |
| Gabapentin | 231 | $2,056 |
| Carbamazepine ErCarbamazepine | 14 | $1,986 |
| Levetiracetam | 84 | $1,877 |
| Galantamine Hbr | 22 | $1,732 |
| Duloxetine Hcl | 156 | $1,577 |
| Sumatriptan Succinate | 114 | $1,423 |
| Topiramate | 133 | $1,257 |
| Pregabalin | 83 | $1,137 |
| Carbamazepine | 37 | $1,046 |
| Primidone | 24 | $943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $109 | $64,15211 claims |
| AbbVieQulipta | $1,586 | $34,37829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 nurse practitioner providers in Nevada.
Other nurse practitioner in Las Vegas
- Melanie SpeedLas Vegas$80K
- Shelley MilesLas Vegas$34K
- Nasslynne LenzLas Vegas$32K
- Shannon SouthwickLas Vegas$32K
- Bonnie KwanLas Vegas$30K
- Amanda RalphLas Vegas$26K
- Teodoro AgtayLas Vegas$25K
- Katherine WhitmireLas Vegas$18K
- Jennifer WalshLas Vegas$18K
- Andrew VolinLas Vegas$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.